1 recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
Follow Mary Feng, MD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma Durvalumab, Hypofractionated Radiation Therapy, Tremelimumab - Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 2 | Recruiting | Mary Feng, MD | 21 | 2022-02-04 | 2025-12-08 |
Disulfides (1) · Immunoglobulin G (1) · Radiation Dose Hypofractionation (1) · durvalumab (1) · tremelimumab (1)
United States (1)